Taking people in United StatesPhase 1
Tests BHV-1400 for IgA nephropathy, a kidney disease
Checks whether BHV-1400 is safe in adults with IgA nephropathy.
Plain-language title generated from the registry record
Registry title: Study of BHV-1400 in IgA Nephropathy
Key facts
- Where
- Chesterfield, Dakota Dunes, Farmington, Hinsdale, Houston, Indianapolis, Lawrenceville, Miami Lakes, Orlando, Pembroke Pines, Salt Lake City, and Shelby, United StatesSee the 14 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07054684, who can take part
Where in United States
- ChesterfieldChesterfield, United StatesTaking people
- Dakota DunesDakota Dunes, United StatesTaking people
- FarmingtonFarmington, United StatesTaking people
- HinsdaleHinsdale, United StatesTaking people
- HoustonHouston, United StatesTaking people
- HoustonHouston, United StatesTaking people
- IndianapolisIndianapolis, United StatesTaking people
- LawrencevilleLawrenceville, United StatesTaking people
- Miami LakesMiami Lakes, United StatesTaking people
- Miami LakesMiami Lakes, United StatesTaking people
- OrlandoOrlando, United StatesTaking people
- Pembroke PinesPembroke Pines, United StatesTaking people
- Salt Lake CitySalt Lake City, United StatesTaking people
- ShelbyShelby, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Biohaven Therapeutics Ltd.
- Trial code
- NCT07054684
- Record updated
- 23 June 2026
- Original description
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).Read full original descriptionShow less
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Inclusion: Participants must have biopsy-confirmed IgA Nephropathy.
Exclusion: Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause; Any secondary IgAN.